Hims & Hers Health (NYSE: HIMS) disappointed investors with its Q1 FY2026 earnings, reporting a staggering EPS loss of 44 cents compared to the expected profit of 4 cents, alongside revenues of approximately $608 million that fell short of the $617 million consensus. This double miss triggered a nearly 23% drop in the stock, highlighting investor concerns over the company’s profitability despite its growth potential.
Despite the recent setbacks, Hims & Hers is positioned within high-growth telehealth markets, which are projected to expand at a CAGR of nearly 25% through 2030. The company is also set to benefit from its strategic partnership with Novo Nordisk in the GLP-1 weight-loss drug sector, with management raising its full-year revenue guidance to between $2.8 billion and $3 billion. Additionally, the planned acquisition of Eucalyptus is expected to enhance its international footprint and revenue growth.
For market professionals, Hims & Hers represents a potential buy-low opportunity, particularly given its average annual revenue growth of over 74% in the past five years and the prospect of significant upside, with analysts suggesting a 12-month price target of $29.37—indicating a potential 31% increase from current levels.
Source: marketbeat.com